New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer

被引：5

作者：

Arrieta, Oscar ^{[1
]}

Lucia Zatarain-Barron, Zyanya ^{[1
]}

Cardona, Andres F. ^{[2
,3
]}

机构：

[1] Inst Nacl Cancerol INCan, Thorac Oncol Unit, Mexico City 14080, DF, Mexico

[2] Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

[3] Clin Country, Clin & Traslat Oncol Grp, Inst Oncol, Bogota, Colombia

来源：

LANCET ONCOLOGY | 2020年 / 21卷 / 05期

关键词：

D O I：

10.1016/S1470-2045(20)30097-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：605 / 607

页数：3

共 10 条

[1]

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study [J].

Calvo, E. ;

Moreno, V. ;

Flynn, M. ;

Holgado, E. ;

Olmedo, M. E. ;

Criado, M. P. Lopez ;

Kahatt, C. ;

Lopez-Vilarino, J. A. ;

Siguero, M. ;

Fernandez-Teruel, C. ;

Cullell-Young, M. ;

Matos-Pita, A. Soto ;

Forster, M. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2559-2566

[2]

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line [J].

Farago, Anna F. ;

Drapkin, Benjamin J. ;

Antonio Lopez-Vilarino de Ramos, Jose ;

Galmarini, Carlos M. ;

Nunez, Rafael ;

Kahatt, Carmen ;

Paz-Ares, Luis .

FUTURE ONCOLOGY, 2019, 15 (03) :231-239

[3]

Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients [J].

Horita, Nobuyuki ;

Yamamoto, Masaki ;

Sato, Takashi ;

Tsukahara, Toshinori ;

Nagakura, Hideyuki ;

Tashiro, Ken ;

Shibata, Yuji ;

Watanabe, Hiroki ;

Nagai, Kenjiro ;

Inoue, Miyo ;

Nakashima, Kentaro ;

Ushio, Ryota ;

Shinkai, Masaharu ;

Kudo, Makoto ;

Kaneko, Takeshi .

SCIENTIFIC REPORTS, 2015, 5

[4]

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].

Horn, L. ;

Mansfield, A. S. ;

Szczesna, A. ;

Havel, L. ;

Krzakowski, M. ;

Hochmair, M. J. ;

Huemer, F. ;

Losonczy, G. ;

Johnson, M. L. ;

Nishio, M. ;

Reck, M. ;

Mok, T. ;

Lam, S. ;

Shames, D. S. ;

Liu, J. ;

Ding, B. ;

Lopez-Chavez, A. ;

Kabbinavar, F. ;

Lin, W. ;

Sandler, A. ;

Liu, S. V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229

[5]

NCCN Guidelines® Insights Small Cell Lung Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines [J].

Kalemkerian, Gregory P. ;

Loo, Billy W., Jr. ;

Akerley, Wallace ;

Attia, Albert ;

Bassetti, Michael ;

Boumber, Yanis ;

Decker, Roy ;

Dobelbower, M. Chris ;

Dowlati, Afshin ;

Downey, Robert J. ;

Florsheim, Charles ;

Ganti, Apar Kishor P. ;

Grecula, John C. ;

Gubens, Matthew A. ;

Hann, Christine L. ;

Hayman, James A. ;

Heist, Rebecca Suk ;

Koczywas, Marianna ;

Merritt, Robert E. ;

Mohindra, Nisha ;

Molina, Julian ;

Moran, Cesar A. ;

Morgensztern, Daniel ;

Pokharel, Saraswati ;

Portnoy, David C. ;

Rhodes, Deborah ;

Rusthoven, Chad ;

Santana-Davila, Rafael ;

Williams, Charles C., Jr. ;

Hoffmann, Karin G. ;

Hughes, Miranda .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (10) :1171-1182

[6]

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J].

Paz-Ares, Luis ;

Dvorkin, Mikhail ;

Chen, Yuanbin ;

Reinmuth, Niels ;

Hotta, Katsuyuki ;

Trukhin, Dmytro ;

Statsenko, Galina ;

Hochmair, Maximilian J. ;

Ozguroglu, Mustafa ;

Ji, Jun Ho ;

Voitko, Oleksandr ;

Poltoratskiy, Artem ;

Ponce, Santiago ;

Verderame, Francesco ;

Havel, Libor ;

Bondarenko, Igor ;

Kazarnowicz, Andrzej ;

Losonczy, Gyorgy ;

Conev, Nikolay V. ;

Armstrong, Jon ;

Byrne, Natalie ;

Shire, Norah ;

Jiang, Haiyi ;

Goldman, Jonathan W. ;

Batagelj, Emilio ;

Casarini, Ignacio ;

Pastor, Anea Viviana ;

Sena, Susana Noemi ;

Zarba, Juan Jose ;

Burghuber, Otto ;

Hartl, Sylvia ;

Hochmair, Maximilian J. ;

Lamprecht, Bernd ;

Studnicka, Michael ;

Schlittler, Luis Alberto ;

de Oliveira, Fabricio Augusto Martinelli ;

Calabrich, Aknar ;

Girotto, Gustavo Colagiovanni ;

Dos Reis, Peo ;

Gorini, Carlos Fausto Nino ;

De Marchi, Peo Rafael Martins ;

Baldotto, Clarissa Serodio da Rocha ;

Sette, Claudia ;

Zukin, Mauro ;

Conev, Nikolay V. ;

Dudov, Assen ;

Ilieva, Rumyana ;

Koynov, Krassimir ;

Krasteva, Rositsa ;

Tonev, Ivan .

LANCET, 2019, 394 (10212) :1929-1939

[7]

Quan AL, 2004, ONCOLOGY-NY, V18, P961

[8]

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial [J].

Trigo, Jose ;

Subbiah, Vivek ;

Besse, Benjamin ;

Moreno, Victor ;

Lopez, Rafael ;

Sala, Maria Angeles ;

Peters, Solange ;

Ponce, Santiago ;

Fernandez, Cristian ;

Alfaro, Vicente ;

Gomez, Javier ;

Kahatt, Carmen ;

Zeaiter, Ali ;

Zaman, Khalil ;

Boni, Valentina ;

Arrondeau, Jennifer ;

Martinez, Maite ;

Delord, Jean-Pierre ;

Awada, Ahmad ;

Kristeleit, Rebecca ;

Olmedo, Maria Eugenia ;

Wannesson, Luciano ;

Valdivia, Javier ;

Rubio, Maria Jesus ;

Anton, Antonio ;

Sarantopoulos, John ;

Chawla, Sant P. ;

Mosquera-Martinez, Joaquin ;

D'Arcangelo, Manolo ;

Santoro, Armando ;

Villalobos, Victor M. ;

Sands, Jacob ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2020, 21 (05) :645-654

[9]

The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability [J].

Tumini, Emanuela ;

Herrera-Moyano, Emilia ;

San Martin-Alonso, Marta ;

Barroso, Sonia ;

Galmarini, Carlos M. ;

Aguilera, Andres .

MOLECULAR CANCER RESEARCH, 2019, 17 (03) :773-782

[10]

Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity [J].

Xie, Wei ;

Forveille, Sabrina ;

Iribarren, Kristina ;

Sauvat, Allan ;

Senovilla, Laura ;

Wang, Yan ;

Humeau, Juliette ;

Perez-Lanzon, Maria ;

Zhou, Heng ;

Martinez-Leal, Juan F. ;

Kroemer, Guido ;

Kepp, Oliver .

ONCOIMMUNOLOGY, 2019, 8 (11)

← 1 →